SCHEDULE: D. E. Shaw Discloses 1.9% Stake in Sarepta Therapeutics

D. E. Shaw & Co., L.P. and David E. Shaw have reported a 1.9% beneficial ownership stake in Sarepta Therapeutics, Inc., totaling 2,007,025 shares.

Summary

• D. E. Shaw & Co., L.P. and David E. Shaw beneficially own 2,007,025 shares of Sarepta Therapeutics, Inc. common stock.
• This ownership represents 1.9% of the outstanding class of securities.
• The reporting persons have shared voting power over 1,984,525 shares and shared dispositive power over 2,007,025 shares.
• The shares are held through D. E. Shaw Oculus Portfolios, L.L.C., D. E. Shaw Valence Portfolios, L.L.C., and D. E. Shaw Investment Management, L.L.C.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of Sarepta Therapeutics, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: This is a neutral, routine disclosure of beneficial ownership, indicating a passive investment stake below the 5% threshold that would typically trigger more scrutiny or activist intent.

Future Outlook

NA

Industry Context

This filing represents a routine disclosure of institutional ownership by D. E. Shaw & Co., L.P., a prominent global investment and technology development firm, in Sarepta Therapeutics, a biotechnology company focused on gene therapy for rare diseases. Such disclosures are common for large investment firms managing diverse portfolios.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception of the stock's liquidity and institutional interest.

Key Dates

Keywords

Sarepta Therapeutics, D. E. Shaw, David E. Shaw, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, SRPT